TIGL Lead Scientist Part Time

Boston, MA, USA
Dana-Farber Cancer Institute
The Translational Immunogenomics Lab (TIGL) within DFCI uses state-of-the-art genomic technologies to assess the response of the immune system to cancer and therapy. TIGL evaluates the latest developments in the field, implements the optimal methods for the task at hand, and invents methods when current approaches are inadequate. The overall goal of TIGL is to use genomic technology to evaluate biomarkers of response and resistance to immunotherapy. One particular focus is discovering patient-specific neoantigens, understanding the details and consequences of interactions between neoantigens and T cells, and

Source: